14th Aug 2015 08:20
LONDON (Alliance News) - Ergomed PLC said Friday that its co-development partner expects the second interim analysis of its phase III study of zoptarelin doxorubicin in endometrial cancer to be completed in early October.
Ergomed's co-development partner is NASDAQ-listed Aeterna Zentaris Inc.
"We believe that zoptarelin doxorubicin has the potential to become the first FDA approved medical therapy for advanced, recurrent endometrial cancer," said Chief Medical and Chief Scientific Officer of Aeterna Zentaris Richard Sachse in a statement.
Shares in Ergomed were untraded Friday morning. It last closed at 182.00 pence.
By Hana Stewart-Smith; [email protected]; @hanassallnews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
ERGO.L